

(51) International Patent Classification:
C07K 16/30 (2006.01)(21) International Application Number:
PCT/US2021/012846(22) International Filing Date:
08 January 2021 (08.01.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/959,862	10 January 2020 (10.01.2020)	US
62/959,877	10 January 2020 (10.01.2020)	US
62/959,882	10 January 2020 (10.01.2020)	US
63/043,752	24 June 2020 (24.06.2020)	US
63/043,754	24 June 2020 (24.06.2020)	US
63/043,749	24 June 2020 (24.06.2020)	US

(71) Applicant: **LYCIA THERAPEUTICS, INC.** [US/US];
681 Gateway Blvd., 3rd Floor, South San Francisco, CA
94080 (US).(72) Inventors: **BUSCH, Brett, Bradley**; c/o Lycia Therapeu-
tics, Inc., 681 Gateway Blvd., 3rd Floor, South San Fran-

cisco, CA 94080 (US). **ERNST, Justin, Thomas**; c/o Ly-
cia Therapeutics, Inc., 681 Gateway Blvd., 3rd Floor, South
San Francisco, CA 94080 (US). **PACKARD, Garrick, K.**;
c/o Lycia Therapeutics, Inc., 681 Gateway Blvd., 3rd Floor,
South San Francisco, CA 94080 (US). **LEWIS, Jason, G.**;
c/o Lycia Therapeutics, Inc., 681 Gateway Blvd., 3rd Floor,
South San Francisco, CA 94080 (US). **TURTLE, Eric, D.**;
c/o Lycia Therapeutics, Inc., 681 Gateway Blvd., 3rd Floor,
South San Francisco, CA 94080 (US).

(74) Agent: **FOULDS, Glenn, J.** et al.; Fenwick & West LLP,
801 California Street, Mountain View, CA 94041 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES




FIG. 26

(57) Abstract: The present disclosure provides a class of compounds including a ligand moiety that specifically binds to a cell surface receptor, such as a mannose-6-phosphate receptor (M6PR) or a cell surface asialoglycoprotein receptor (ASGPR). The cell surface M6PR or ASGPR binding compounds can trigger the receptor to internalize into the cell a bound compound. The ligand moieties of this disclosure can be linked to a variety of moieties of interest without impacting the specific binding to, and function of, the cell surface receptor, e.g., M6PR or ASGPR. Also provided are compounds that are conjugates of the ligand moieties linked to a biomolecule, such as an antibody, which conjugates can harness cellular pathways to remove specific proteins of interest from the cell surface or from the extracellular milieu. Also provided are methods of using the conjugates to target a polypeptide of interest for sequestration and/or lysosomal degradation.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*